Preservation of sexual function following Rezum® therapy for LUTS/BPH too good to be true? Real world outcomes from 181 cases
BAUS ePoster online library. Connor M. 06/21/21; 319072; p3-4
Disclosure(s): Martin J. Connor research is supported by the Wellcome Trust and University College London Hospitals (UCLH) Charity
Mr. Martin John Connor
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction: Preservation of sexual function whilst alleviating bothersome lower urinary tract symptoms secondary to benign prostatic hyperplasia is a major attraction for men consenting to transurethral water vapour treatment (Rezum®). There is limited understanding of this. We report on de novo erectile dysfunction, retrograde ejaculation (Rej), anejaculation (Anej), painful ejaculation (Pej), decreased volume of ejaculate (DVe) and patient-reported outcomes measures (PROMS) of erectile function.
Materials and Methods: Consecutive patients were identified at a single tertiary centre, who underwent Rezum® (Aug/2017-Dec/2019). Patients with a history of AUR, prior BPH-surgery, clinically significant prostate cancer, LTC or prostatitis were excluded. Paired-IIEF-5 at: Initial [4-6 months]; Early [7-12 months]; Medium [13-18 months]; or Late [> 18 months] follow-up. Wilcoxon signed-rank test (SPSS v26.0).
Results: 181 / 310 (58.4%) patients met inclusion. Pre-operative median age, PVol, QMax (ml/s) and PVR (ml) were 69 yrs (IQR 11.5), 55 cc (IQR 29), 9.4 (IQR 5.5), 137.5 (IQR 125), respectively. De novo erectile dysfunction was not reported (0/181). Ejaculatory function results: 3/181 Rej (1.7%), 5/181 Anej (2.8%), 2/181 Pej (1.1%), 2/181 DVe (1.1%), respectively. Pre-operative IIEF-5 was 14.9 points (SD 7.1). In 153/181 (84.5%) paired-IIEF-5 were available, at: Initial 20.2% (31/153), Early 43.7% (67/153), Medium 24.8% (38/153) and Late 11.1% (17/153) follow-up, respectively. No significant reduction in paired-IIEF-5 occurred at any follow-up (p>0.05). Four (2.2%; 4/181) Clavien-Dindo >/= Grade II complications.
Conclusion: These findings support previous trial data suggesting no evidence of post-operative de novo erectile dysfunction, whilst preservation of aspects of ejaculatory function in up to 97%.
Materials and Methods: Consecutive patients were identified at a single tertiary centre, who underwent Rezum® (Aug/2017-Dec/2019). Patients with a history of AUR, prior BPH-surgery, clinically significant prostate cancer, LTC or prostatitis were excluded. Paired-IIEF-5 at: Initial [4-6 months]; Early [7-12 months]; Medium [13-18 months]; or Late [> 18 months] follow-up. Wilcoxon signed-rank test (SPSS v26.0).
Results: 181 / 310 (58.4%) patients met inclusion. Pre-operative median age, PVol, QMax (ml/s) and PVR (ml) were 69 yrs (IQR 11.5), 55 cc (IQR 29), 9.4 (IQR 5.5), 137.5 (IQR 125), respectively. De novo erectile dysfunction was not reported (0/181). Ejaculatory function results: 3/181 Rej (1.7%), 5/181 Anej (2.8%), 2/181 Pej (1.1%), 2/181 DVe (1.1%), respectively. Pre-operative IIEF-5 was 14.9 points (SD 7.1). In 153/181 (84.5%) paired-IIEF-5 were available, at: Initial 20.2% (31/153), Early 43.7% (67/153), Medium 24.8% (38/153) and Late 11.1% (17/153) follow-up, respectively. No significant reduction in paired-IIEF-5 occurred at any follow-up (p>0.05). Four (2.2%; 4/181) Clavien-Dindo >/= Grade II complications.
Conclusion: These findings support previous trial data suggesting no evidence of post-operative de novo erectile dysfunction, whilst preservation of aspects of ejaculatory function in up to 97%.
Introduction: Preservation of sexual function whilst alleviating bothersome lower urinary tract symptoms secondary to benign prostatic hyperplasia is a major attraction for men consenting to transurethral water vapour treatment (Rezum®). There is limited understanding of this. We report on de novo erectile dysfunction, retrograde ejaculation (Rej), anejaculation (Anej), painful ejaculation (Pej), decreased volume of ejaculate (DVe) and patient-reported outcomes measures (PROMS) of erectile function.
Materials and Methods: Consecutive patients were identified at a single tertiary centre, who underwent Rezum® (Aug/2017-Dec/2019). Patients with a history of AUR, prior BPH-surgery, clinically significant prostate cancer, LTC or prostatitis were excluded. Paired-IIEF-5 at: Initial [4-6 months]; Early [7-12 months]; Medium [13-18 months]; or Late [> 18 months] follow-up. Wilcoxon signed-rank test (SPSS v26.0).
Results: 181 / 310 (58.4%) patients met inclusion. Pre-operative median age, PVol, QMax (ml/s) and PVR (ml) were 69 yrs (IQR 11.5), 55 cc (IQR 29), 9.4 (IQR 5.5), 137.5 (IQR 125), respectively. De novo erectile dysfunction was not reported (0/181). Ejaculatory function results: 3/181 Rej (1.7%), 5/181 Anej (2.8%), 2/181 Pej (1.1%), 2/181 DVe (1.1%), respectively. Pre-operative IIEF-5 was 14.9 points (SD 7.1). In 153/181 (84.5%) paired-IIEF-5 were available, at: Initial 20.2% (31/153), Early 43.7% (67/153), Medium 24.8% (38/153) and Late 11.1% (17/153) follow-up, respectively. No significant reduction in paired-IIEF-5 occurred at any follow-up (p>0.05). Four (2.2%; 4/181) Clavien-Dindo >/= Grade II complications.
Conclusion: These findings support previous trial data suggesting no evidence of post-operative de novo erectile dysfunction, whilst preservation of aspects of ejaculatory function in up to 97%.
Materials and Methods: Consecutive patients were identified at a single tertiary centre, who underwent Rezum® (Aug/2017-Dec/2019). Patients with a history of AUR, prior BPH-surgery, clinically significant prostate cancer, LTC or prostatitis were excluded. Paired-IIEF-5 at: Initial [4-6 months]; Early [7-12 months]; Medium [13-18 months]; or Late [> 18 months] follow-up. Wilcoxon signed-rank test (SPSS v26.0).
Results: 181 / 310 (58.4%) patients met inclusion. Pre-operative median age, PVol, QMax (ml/s) and PVR (ml) were 69 yrs (IQR 11.5), 55 cc (IQR 29), 9.4 (IQR 5.5), 137.5 (IQR 125), respectively. De novo erectile dysfunction was not reported (0/181). Ejaculatory function results: 3/181 Rej (1.7%), 5/181 Anej (2.8%), 2/181 Pej (1.1%), 2/181 DVe (1.1%), respectively. Pre-operative IIEF-5 was 14.9 points (SD 7.1). In 153/181 (84.5%) paired-IIEF-5 were available, at: Initial 20.2% (31/153), Early 43.7% (67/153), Medium 24.8% (38/153) and Late 11.1% (17/153) follow-up, respectively. No significant reduction in paired-IIEF-5 occurred at any follow-up (p>0.05). Four (2.2%; 4/181) Clavien-Dindo >/= Grade II complications.
Conclusion: These findings support previous trial data suggesting no evidence of post-operative de novo erectile dysfunction, whilst preservation of aspects of ejaculatory function in up to 97%.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}